

13	An Abstract Analysis: Obesity Treatment and Trends, Today and Tomorrow
13	Atlas Shrugged . . . and Slumped Under the Weight of a Global Epidemic
14	Obesity Can't Be Cured, Resolved or Wished Away by Re-defining it
15	Drugs and Devices in the Obesity's Market's Growing Future
17	The Overweight Population . . . Epidemic, Risk Factor or Misdiagnosis?
22	Obesity Challenges Are Smoking for a Dubious Title
22	Childhood Obesity Is Dooming a Generation Before it Gets Started
23	A World Equally Hungry and Overfed
27	Does the BMI Contrive an Artificial Market for Drug Developers, Med-tech Purveyors and Physicians?
29	Does BMI Settle the Debate, or Is the Visual Proof All Around Us?
29	We Won't Stop Eating, So We Must Keep Researching
29	Sex, Sleep and Weight . . . Prurient Interests Augment Serious Markets
30	The Weight of the World to Come: Challenges and Issues of the Future Market
33	Obesity Drugs: An Underweight Market Seeks Big Opportunitites from a Growing Problem
35	Top Obesity Candidates Reveal Promising Data, but Get No Promises from Pharma
38	Solving the Obesity Compound Conundrum: Where's Big Pharma?
39	How Much Longer? Pharma Resists the Lure of an Underserved Goldmine Market
40	Combination Drugs Could Deliver Twice the Efficacy and Billions in Market Potential
41	Arena Pharmaceuticals – lorcaserin
44	Vivus – Qnexa
48	Orexigen Therapeutics – Contrave
50	Novo Nordisk – Victoza
50	Alizyme – cetilistat
51	Amylin Pharmaceuticals – pramlintide and metreleptin
51	Obecure – Histalean
52	Orexigen Therapeutics – Empatic
53	NeuroSearch – tesofensine
53	Surface Logix – SLx-4090
53	Arete Therapeutics – AR9281
53	Shionogi – S-2367
53	Amylin Pharmaceuticals and Takeda Pharmaceutical – davalintide
53	TransTech Pharma – TTP435
54	7TM Pharma – TM30339
54	7TM Pharma – Obinepitide (TM30338)
54	OSI Pharmaceuticals – PSN821
54	OSI Pharmaceuticals – PSN602
54	AstraZeneca – AZD4017

54	AstraZeneca – AZD8329
54	AstraZeneca – AZD7687
54	Emisphere Technologies – Oral Peptide YY (PYY)
54	TransTech Pharma – HPP404
54	Surface Logix – SLx-2119
55	Zafgen – ZGN-433
55	Early Stage Development Efforts in Obesity
55	7TM Pharma – TM38837
55	Aegis Therapeutics
55	Agios Pharmaceuticals
55	AstraZeneca
55	BioVista
56	Braasch Biotech
56	Cambridge Biotechnology / Proximagen Neuroscience
56	CeNeRx BioPharma
56	Colby Pharmaceutical – CPC-410
56	Compellis Pharmaceuticals – CP404
56	Corcept Therapeutics – CORT 108297
57	DeveloGen
57	Elixir Pharmaceuticals
57	Fasgen
57	Genfit – TGFTX2
58	Halsa Pharmaceuticals – ZAG
58	Intercept Pharmaceuticals – INT-777
58	Isis Pharmaceuticals
58	Marcadia Biotech
58	Merck
59	Myriad Pharmaceuticals – MPI-0485520
59	Palatin Technologies
59	RXi Pharmaceuticals
59	Sirona Biochem
60	Transition Therapeutics
60	Unigene Laboratories – UGP281
60	Ventana Biotech
60	Xenon Pharmaceuticals
60	XOMA – XOMA 052
60	Zealand Pharma – ZP2929
60	ZenBio
61	Znomics
61	Discontinued Products and Programs Are Prevalent in Obesity Space
61	Athersys – ATHX-105
61	Genaera – MSI-1436
61	MDRNA – PPY(3-36)

62	Merck – taranabant
62	Neurogen – NGD-4715
62	Orexigen Therapeutics – OREX-003
63	Pfizer – CP-945,598
63	Sanofi-Aventis – Acomplia
63	Vernalis – V24343
<hr/>	
65	Unfortunately, It's a Growth Market: Limitless Opportunity Seen in Obesity Devices
65	Devices Hold Top Market Billing Over Pharma Solutions for Obesity
67	Benefits of Bariatric Surgery for the Morbidly Obese
67	Bariatric Surgery Meets Cost Effectiveness Standards
67	Bariatric Surgery Coverage Is Clarified
68	Study: Bariatric Surgery as Safe for Teens as it Is for Adults
69	Economics, Diabetes and Bariatric Surgery
70	Revision Surgery Is a New Market
71	USGI Medical – IOP
72	C.R. Bard – EndoCinch
73	EndoGastric Solutions – StomaphyX
73	Adjustable Gastric Bands Fill Need, Face Market Risk
74	Allergan – Lap-Band
76	Ethicon Endo-Surgery – Realize
77	Gastric Bypass vs. Gastric Band
78	Less-Invasive Products Are New Market Segments for Bariatric Surgery
78	Minimally Invasive Procedures
78	GI Dynamics – EndoBarrier
80	Satiety – TOGA
81	USGI Medical – IOP
81	Silhouette Medical – nObese
82	Endosphere
82	BAROnova – TransPyloric Shuttle
82	ValenTx
82	Other Surgical Platforms
82	SafeStitch Medical
83	TransEnterix – Spider System
83	EndoVx
83	Neuromodulation Is an Emerging Market
83	EnteroMedics – Vbloc
87	MetaCure – Tantalus
87	IntraPace – Abiliti
87	Leptos Biomedical – IPG
88	Sentinel Group – Full Sense
88	StimPulse

88	NeuroSigma
88	Balloons and Space-Filling Surgical Products
88	Allergan – Orbera
89	Helioscopie – Heliosphere
89	Spatz FGIA – Adjustable Balloon System
90	ReShape Medical – ReShape Balloon
90	Fulfillium
90	Other Space-Filling Products
90	Tulip Medical
90	BaroSense – TERIS
90	Gelesis
91	Sleeve Gastrectomy – An Old Procedure Revived
91	Lifestyle Medicine
92	New Markets Opening for Existing Products
92	Diabetes Control Is Another New Market
93	Body Composition Analyzers
93	Bruker Optics
93	Cosmed
93	Echo Medical Systems
93	Hologic
94	ImpediMed
94	Jawon Medical
94	Korr Medical Technologies
94	Life Measurement
94	Tanita
94	Bodystat
94	Metabolic and Other Testing Equipment
94	ActiGraph
94	Cosmed
94	Korr Medical Technologies
94	Microlife USA
94	Mini Mitter
94	Sable Systems
95	Seahorse Bioscience
95	Zen-Bio
95	Behavior Modification for Weight Control
95	BodyMedia – SenseWear
95	GE Healthcare Lunar
96	Aipermon
96	iWhisper
96	MEND Central
96	Assisting Weight-Loss Efforts
96	Aestis

97	Movea
97	Novartis Medical Nutrition
97	Phoenix Care
97	Suzuken
97	Obesity-Related Diagnostics
97	Interleukin Genetics
98	Quantomix
98	Other Obesity Diagnostics
99	Science Highlights: Recent Research Breakthroughs in the Battle of the Bulge
99	Fat-Fighting Enzyme Can Play Havoc with Cancer Cells
99	For Bone, Appetite Regulators, It's Location, Location, Location
100	Insulin, Body Temp Related
100	Study Shows Fat Around Heart Decreases Heart Functions
100	Starting Weight a Factor in Bypass Surgery
100	New Obesity Target Involves Use of a 'Molecular Shunt'
101	Studies: Links Among Obesity, Inflammation, Insulin Resistance
102	New Factor for Converting Cells to 'Good' Brown Fat Identified
102	Targets Are Identified for Battle of the Bulge
103	In Feeding, Metabolism, It's All About Location
104	Hypothalamic Overeating Gene Pegged
104	Systems Biology Approach Finds Novel Obesity Genes
105	Peripheral Endocannabinoids Linked to Fatty Liver Disease
106	New Research Implicates Lipid Metabolites in Insulin Resistance
106	\$50M Sequence Project to Map Genomes in 1,000 People
107	Study Relates Gastric Surgery to Diabetes
109	Obesity Data
125	Index

LIST OF TABLES

13 Introduction and Analysis

14	Cost of Lost Productivity Related to Overweight and Obesity
14	Cost of Overweight and Obesity
15	Costs Related to Overweight and Obesity, by Disease
17	Annual Soft Drink Production in the U.S.
18	Defining Overweight and Obesity for Adults
18	U.S. Obesity Prevalence by Age, Race/Ethnicity and Sex, 2005-2006
19	Overweight and Obese, by Age, U.S., 1971-2006
20	Classification of Obesity and Risks of Co-Morbidities
20	U.S. Obesity Prevalence by Age and Sex, 2005-2006
20	Percentage of Disease Cases Related to Obesity
21	Health Consequences of Obesity
21	Obesity Is Linked to a Significant Increase in Chronic Conditions
22	Obese Individuals Spend More on Health Care Than Smokers and Drinkers
23	Contextual Influences on the Development of Childhood Obesity
24	Global Hunger Statistics
25	Percentage of Total Population That Is Obese, by Country
26	Most Undernourished Countries, by Percent of Population Undernourished
27	Percentage of Overweight Women in Developing Countries, Compared to U.S.
27	The Inverted U of Wealth and Obesity
28	Defining Obesity
28	Health Insurance Coverage, U.S., Under 65 Years Old, 1984-2006

33 Obesity Drugs: Big Opportunities for a Growing Problem

33	Obesity Rankings by State
33	Body Mass Index of U.S. Population
33	Aggregate Medical Spending Attributable to Overweight and Obesity
34	Estimated Adult Obesity-Attributable Percentages and Expenditures by State
35	Rising Costs of Obesity
35	Medications That Promote Weight Loss
36	Percentage of U.S. Adults Who Are Overweight or Obese
36	Percentage of U.S. Adults Who Are Obese
36	Percentage of U.S. Adults Who Are at a Healthy Weight
37	Company Survey Asking, 'What Aspects of Obesity Do Your Discovery Research and Drug Candidates Address?'
39	Obesity Drugs in Development
41	Market for Prescription Obesity Drugs, 2007-2017
45	Percentage of Patients with Obstructive Sleep Apnea

65 Unfortunately, It's a Growth Market: Limitless Opportunity Seen in Obesity Devices

65	Device and Drug Sales and Projection in the Clinical Management of Obesity, 2004-2015
----	---

66	Balance of Drug/Device Sales in the Clinical Management of Obesity, 2004-2015
66	Bariatric Surgical Devices and Pharmaceuticals in Obesity, Worldwide Sales and Projection, 2006-2015
67	Cost Effectiveness of Bariatric Surgery
68	Responses from Family Practitioners Regarding Obesity Surgery
68	Teen Surgeries for Obesity Are Increasing: Number of Bariatric Procedures for U.S. Teenagers
69	Top Reasons Patients Don't Have Bariatric Surgery
69	Number of Bariatric Surgeries in the U.S., 1993-2008
69	Relationship Between Body Mass Index and Risk of Type II Diabetes Mellitus
71	Products for Endoluminal Pouch Reduction
77	Invasiveness of Roux-en-Y Gastric Bypass vs. Laproscopic Adjustable Gastric Banding
84	Neuromodulation Products and Companies
89	Space-Filling Products to Treat Obesity
91	Ideal Bariatric Procedure Attributes
92	Endoluminal Products for Weight Loss and Diabetes Control
93	Companies with Interventional Therapies for Obesity and Diabetes in Development

109 Obesity Data

109	Personal Health Expenditures, by Source of Funds and Type, U.S. 2006
109	Obesity as a Function of Income and Education
110	Insulin Sensitivity Improves with Weight Loss in Patients with Type II Diabetes
110	Strength of Evidence on Lifestyle Factors and Risk of Developing Type II Diabetes
111	Strength of Evidence on Lifestyle Factors and the Risk of Developing Cancer
111	Strength of Evidence on Lifestyle Factors and Risk of Developing Cardiovascular Diseases
112	CDC's Recommended Community Strategies to Prevent Obesity in the U.S.
114	Percentage of Obese Subjects Reporting Depression
114	Percentage of People Who Are Depressed, by Relative Body Weight
114	Relation Between Obesity and Depression
115	Is Obesity an Epidemic in the U.S.?
115	Higher Health Care Costs for Businesses
116	What's Behind the Obesity Epidemic?
117	Health Care Costs of Obesity
118	Obesity's Impact on Health
120	Global Hunger and Food Statistics
120	Countries That Received the Most U.S. Foreign Aid in 2008
121	Number of Undernourished People in the World, 1969/71-2009
121	Global and Regional per Capita Food Consumption
121	Undernourishment in 2009, by Region
122	Obesity Deals and Data
124	Total and Older Population, U.S.: 1950-2050